Celecoxib to prevent restenosis - results from the COREA-TAXUS trial

Doggrell, S 2008, 'Celecoxib to prevent restenosis - results from the COREA-TAXUS trial', Expert Opinion on Pharmacotherapy, vol. 9, no. 2, pp. 339-341.


Document type: Journal Article
Collection: Journal Articles

Title Celecoxib to prevent restenosis - results from the COREA-TAXUS trial
Author(s) Doggrell, S
Year 2008
Journal name Expert Opinion on Pharmacotherapy
Volume number 9
Issue number 2
Start page 339
End page 341
Total pages 3
Publisher Informa Healthcare
Abstract Celecoxib inhibits Akt, which is stimulated during restenosis. Cell and animal studies showed that celecoxib inhibited Akt stimulation and restenosis. Recently, the COREA-TAXUS (Effect of Celecoxib on Restenosis after Coronary Angioplasty with Taxus stent) trial was performed in subjects with angina or a positive-stress test receiving paclitaxel-eluting stents. The primary end point at 6 months was the in-stent, late luminal loss, which was 0.49 mm in the celecoxib-treated group; less than the 0.75 mm in the group not treated with celecoxib. The rate of revascularisation of the target lesion was lower in celecoxib-treated subjects (5%) than in the untreated subjects (15%). In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use.
Subject Clinical Pharmacology and Therapeutics
DOI - identifier 10.1517/14656566.9.2.339
Copyright notice © 2008 Informa UK Ltd
ISSN 1465-6566
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 115 Abstract Views  -  Detailed Statistics
Created: Fri, 07 Jan 2011, 09:11:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us